Atria Oyj (OHEL:ATRAV) Research & Development: €0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OHEL:ATRAV Atria Oyj OHEL:ATRAV
73 GF Score
Price €15.62
GF Value €11.67
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Atria Oyj Research & Development?

Atria Oyj OHEL:ATRAV -1.51% 73 Research & Development is €0 Mil as of Mar. 2026. GuruFocus rates OHEL:ATRAV with a GF Score™ of 73/100 and a GF Value™ of €11.67 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Atria Oyj's Research & Development for the three months ended in Mar. 2026 was €0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0 Mil.

Atria Oyj  (OHEL:ATRAV) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Atria Oyj Research & Development Related Terms

Atria Oyj Research & Development Historical Data

* Premium members only.

The historical data trend for Atria Oyj's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atria Oyj Research & Development Chart

Atria Oyj Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Atria Oyj Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OHEL:ATRAV
73GF Score
Atria Oyj OHEL:ATRAV
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atria Oyj Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0 Mil mean?
Atria Oyj (OHEL:ATRAV) has a Research & Development of €0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Atria Oyj and its competitors.
Is Atria Oyj's Research & Development too high?
Atria Oyj's current Research & Development is €0 Mil. Overall, Atria Oyj has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Atria Oyj's Research & Development compare to KHC and GIS?
Atria Oyj's Research & Development of €0 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Consumer Packaged Goods company?
A good Research & Development depends on the Consumer Packaged Goods industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Atria Oyj and its competitors. Atria Oyj's current Research & Development is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atria Oyj stock overvalued right now?
Based on GuruFocus' analysis, Atria Oyj (OHEL:ATRAV) is currently considered Significantly Overvalued. The stock's GF Value™ is €11.67, compared to a current price of €15.62 — trading 33.8% above its estimated fair value. The current Research & Development is €0 Mil. Atria Oyj's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Atria Oyj (OHEL:ATRAV), the current Research & Development is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atria Oyj (OHEL:ATRAV) Overvalued in 2026?

Based on GuruFocus' analysis, Atria Oyj stock appears to be overvalued. The current stock price of €15.62 is trading 33.8% above its estimated GF Value™ of €11.67. GuruFocus considers Atria Oyj to be Significantly Overvalued.

Key valuation signals for OHEL:ATRAV:

  • Research & Development: €0 Mil
  • GF Value™: €11.67 vs. price of €15.62 (33.8% above fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the OHEL:ATRAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Atria Oyj Business Description

Other Exchanges 0IY1:UKAJC:Germany
Address Itikanmaenkatu 3, P.O. Box 900, Seinajoki, FIN, 60060
Atria Oyj manufactures and markets food products, in particular meat products, poultry products, ready meals and food concepts. Its main market area covers Finland, Sweden, Denmark, and Baltic countries. The company's segments include Atria Finland, Atria Sweden, Atria Denmark and Estonia. Atria Finland's product categories include Fresh and consumer packed meat, Poultry products, Cooking products, such as cooking sausages, Sandwich toppings, Convenience food, and Animal feed. Atria Sweden's products include Cold cuts, Sausages, Fresh poultry products, Convenience food, Vegetable and delicatessen products, and Atria Denmark and Estonia's product categories include Meat products, particularly sausages, including cold cuts and spreads, Convenience food, and fresh and consumer-packed meat.
73GF Score

Get the complete analysis for OHEL:ATRAV

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.62
Price
€11.67
GF Value